Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Average Rating of “Reduce” by Brokerages

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned a consensus rating of “Reduce” from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average 12 month target price among […]

Leave a Reply

Your email address will not be published.

Previous post Babcock International Group PLC (LON:BAB) Given Consensus Rating of “Moderate Buy” by Analysts
Next post Brokerages Set Xponential Fitness, Inc. (NYSE:XPOF) Price Target at $27.40